LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER

JA GIETEMA, DT SLEIJFER, PHB WILLEMSE, HS KOOPS, E VANITTERSUM, WMM VERSCHUREN, D KROMHOUT, WJ SLUITER, NH MULDER, EGE DEVRIES

    Research output: Contribution to journalArticleAcademicpeer-review

    88 Citations (Scopus)

    Abstract

    . Objective: To assess cardiovascular risk factors over time in patients who received chemotherapy for disseminated testicular cancer and were apparently cured. . Design: Cohort study. . Setting: Referral center. . Patients: Fifty-seven consecutive patients (median age, 28 years; range, 16 to 43 years) who received cisplatin-containing chemotherapy between 1978 and 1985. . Measurements: Serum cholesterol and high-density lipoprotein (HDL) levels, body mass index (BMI), blood pressure, kidney function, and hormonal status were monitored during follow-up after chemotherapy (median follow-up, 88 months; range, 56 to 143 months). The BMI and cholesterol values obtained 4 to 6 years after chemotherapy were compared with values from a sample of healthy, age-matched Dutch men; the cholesterol level was also compared with that of 31 patients treated with orchidectomy for stage I disease. . Results: The mean cholesterol level in patients at the start of chemotherapy was 3.96 +/- 0.98 mmol/L [153 +/- 38 mg/dL], increasing 4 to 6 years later to 6.12 +/- 1.20 mmol/L [237 +/- 46 mg/dL] (P <0.001); 49 of 57 patients had an elevated low-density lipoprotein (LDL) cholesterol level (> 3.4 mmol/L [130 mg/dL]), with a mean level of 4.47 +/- 1.05 mmol/L [173 +/- 41 mg/dL]. Compared with a sample of healthy Dutch men, the chemotherapy group had an elevated cholesterol level (P <0.05). At 4 to 6 years, the mean HDL cholesterol level was 0.76 +/- 0.18 mmol/L [29 +/- 7 mg/dL], which was low compared with that of the healthy Dutch men (P <0.05). The mean BMI for all patients was 2.8% higher than expected 4 to 6 years after chemotherapy (P <0.01) but was not higher than expected 7 to 10 years after chemotherapy. . Conclusions: In addition to other known late side effects of chemotherapy in patients with testicular cancer, hypercholesterolemia and overweight might represent risk factors for cardiovascular disease in such patients, especially in those who are younger.

    Original languageEnglish
    Pages (from-to)709-715
    Number of pages7
    JournalAnnals of Internal Medicine
    Volume116
    Issue number9
    Publication statusPublished - 1-May-1992

    Keywords

    • TESTICULAR NEOPLASMS
    • CARDIOVASCULAR DISEASES
    • CISPLATIN
    • HYPERCHOLESTEROLEMIA
    • GERM-CELL TUMORS
    • COMBINATION CHEMOTHERAPY
    • DENSITY LIPOPROTEIN
    • RAYNAUDS-PHENOMENON
    • SERUM-CHOLESTEROL
    • RENAL-FUNCTION
    • CISPLATIN
    • VINBLASTINE
    • BLEOMYCIN
    • TOXICITY

    Fingerprint

    Dive into the research topics of 'LONG-TERM FOLLOW-UP OF CARDIOVASCULAR RISK-FACTORS IN PATIENTS GIVEN CHEMOTHERAPY FOR DISSEMINATED NONSEMINOMATOUS TESTICULAR CANCER'. Together they form a unique fingerprint.

    Cite this